bispecific antibodies

Asia
Pharma

Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia

Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu Sep 13, 2024 8:53am
boxing punch blow hit punching bag fight

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study

Sep 8, 2024 11:30am
Asia

Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia

Sep 6, 2024 9:00am
Asia

Merck-Curon, Legend, Amgen—Fierce Pharma Asia

Aug 16, 2024 8:59am
FDA Building

FDA noted 'large number' of missing AEs in Amgen's Imdelltra app

Aug 14, 2024 6:45am
Asia

TROP2 ADCs, Merck-Daiichi, Eisai—Fierce Pharma Asia

Aug 9, 2024 8:25am